INGREZZA patient cases in tardive dyskinesia

See results with INGREZZA from real-world and clinical trial patients

Review tardive dyskinesia (TD) movements across a broad range of adult patients and see the effect of treatment with INGREZZA^® (valbenazine) capsules.

Real-world patient cases

Real-world cases feature patients treated with INGREZZA in clinical practice, and not from the INGREZZA clinical trial program. Treatment decisions were based on healthcare providers’ clinical judgement.

Debra

Major depressive disorder

TD diagnosed woman with major depressive disorder at baseline

TD diagnosed woman at 6 weeks showing improvements on torso movements and body shaking

INGREZZA treatment:

INGREZZA 40 mg (Weeks 0–5) then INGREZZA 80 mg (Weeks 5–6)^a

Medical history:

Woman in her 50s living with severe major depressive disorder
Previously treated with anticholinergic

Relevant treatment:

Second-generation antipsychotics, which resulted in TD

Relevant concomitant treatment at baseline:

Aripiprazole, quetiapine, escitalopram, buspirone, amantadine

TD history:

Developed choreoathetoid movements 6 months prior to treatment with INGREZZA
Presented with predominant trunk movements and abnormal movements of mouth and lips

Note: Not all movements may be visible in these videos

INGREZZA treatment results:

At 6 weeks, HCP noted torso movements and overall body shaking were improved in intensity
HCP notes patient did have some mouth and lip movements

Gloria

Schizoaffective disorder and depression

TD diagnosed woman with schizoaffective disorder and depression at baseline

TD diagnosed woman at 2 weeks showing improvement in movements

TD diagnosed woman at 6 weeks showing reduction in severe hand movements

INGREZZA treatment:

INGREZZA 40 mg (Week 1) then INGREZZA 80 mg (Weeks 2–6)^a

Medical history:

Woman in her 50s living with schizoaffective disorder and depression
History of hospitalization, but circumstances were unknown

Relevant treatment:

Second-generation antipsychotics, which resulted in TD
Currently taking anticholinergic, but medical records were unavailable

Relevant concomitant treatment at baseline:

Paliperidone palmitate 156 mg/QM, fluoxetine 40 mg/QD, benztropine 2 mg/BID

TD history:

Presented with predominant jaw/mouth, hand, and foot movements
Patient’s severe hand movement impacted self-feeding; she was also unable to communicate well due to tongue movements

Note: Not all movements may be visible in these videos

INGREZZA treatment results:

At 2 weeks, symptoms showed improvement and HCP noted patient was more communicative
Patient experienced somnolence
At 4-week follow-up visit, HCP instructed patient to take INGREZZA HS
At 6 weeks, patient’s family noted that movements were improved; HCP noted severe hand movements were reduced, enabling patient to self-feed

^a

Patients were not a part of the INGREZZA clinical trials. Patients’ treating healthcare providers assessed for TD. Recordings were taken before initiation of INGREZZA and at follow-up after 6 weeks of treatment for Debra and after 2 and 6 weeks of treatment for Gloria. Treatment decisions were based on healthcare providers’ clinical judgment. These patients provided consent to allow Neurocrine Biosciences^® to use their images/likeness and medical information.

CONTACT A REPRESENTATIVE

Request an office visit from a Neurocrine representative to see more data and videos and to request INGREZZA samples and patient resources.

CONTACT A REP

Clinical trial videos

In KINECT 3, patients were randomized 1:1:1 to INGREZZA 40 mg, INGREZZA 80 mg, or placebo. Patients randomized to the 80 mg group received 40 mg for the first week.

Sue

Bipolar disorder

TD diagnosed woman living with bipolar disorder at baseline

TD diagnosed woman at 6 weeks showing improvements of 6-point reduction in AIMS score from baseline to Week 6

TD diagnosed woman at 48 weeks showing improvements of 7-point reduction in AIMS score from baseline to Week 48

Clinical trial and treatment group:

KINECT 3,^b INGREZZA 80 mg

Relevant treatment:

Second-generation antipsychotic to treat bipolar disorder, which resulted in TD

Relevant concomitant treatment at baseline:

Ziprasidone 40 mg/QD, clonazepam 1 mg/QD, trazodone 150 mg/QD

Timing of TD diagnosis:

Approximately 1 year prior to study enrollment

Affected body regions:

Jaw, mouth, eyes (predominant), and hands

Note: Not all movements may be visible in these videos

INGREZZA treatment results:

6‑point reduction in AIMS score from baseline to Week 6; 7‑point reduction in AIMS score from baseline to Week 48 (Baseline = 10, Week 6 = 4, Week 48 = 3)

^b

KINECT 3 was a phase 3, multicenter, randomized, double-blind, placebo-controlled (DBPC), parallel, fixed‑dose study to evaluate the efficacy, safety, and tolerability of INGREZZA 40 mg and 80 mg, administered once daily, compared to placebo. If patients were unable to tolerate the 80 mg dose, the investigator could decrease the dose once at any time during the study. If they did not tolerate the new dose, then patients were discontinued from the study. The primary efficacy endpoint was mean change from baseline in Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score at Week 6 on INGREZZA 80 mg.^1,2

Want to see more?
Access exclusive content
with INGREZZA Insider

Register now to access exclusive videos and case study content, plus stay up to date with the latest TD resources and information on INGREZZA.

REGISTER NOW

REFERENCES:

INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc
Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484

Important Information

INDICATION & USAGE

INGREZZA^® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

WARNINGS & PRECAUTIONS

Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Parkinsonism

INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see INGREZZA full Prescribing Information

Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

INDICATION & USAGE

INGREZZA^® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

Important Information

INDICATION & USAGE

INGREZZA^® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

WARNINGS & PRECAUTIONS

Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Parkinsonism

INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see INGREZZA full Prescribing Information